NDLI: Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy

Please wait, while we are loading the content...

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy

Content Provider	PubMed Central
Author	Matthew, Trendowski Fondy, Thomas P.
Abstract	Background Although DNA-directed alkylating agents and related compounds have been a mainstay in chemotherapeutic protocols due to their ability to readily interfere with the rapid mitotic progression of malignant cells, their clinical utility is limited by DNA repair mechanisms and immunosuppression. However, the same destructive nature of alkylation can be reciprocated at the cell surface using novel plasma membrane alkylating agents. Results Plasma membrane alkylating agents have elicited long term survival in mammalian models challenged with carcinomas, sarcomas, and leukemias. Further, a specialized group of plasma membrane alkylating agents known as tetra-O-acetate haloacetamido carbohydrate analogs (Tet-OAHCs) potentiates a substantial leukocyte influx at the administration and primary tumor site, indicative of a potent immune response. The effects of plasma membrane alkylating agents may be further potentiated through the use of another novel class of chemotherapeutic agents, known as dihydroxyacetone phosphate (DHAP) inhibitors, since many cancer types are known to rely on the DHAP pathway for lipid synthesis. Conclusion Despite these compelling data, preliminary clinical trials for plasma membrane-directed agents have yet to be considered. Therefore, this review is intended for academics and clinicians to postulate a novel approach of chemotherapy; altering critical malignant cell signaling at the plasma membrane surface through alkylation, thereby inducing irreversible changes to functions needed for cell survival.
Related Links	http://dx.doi.org/10.1007/s10637-015-0263-1
Ending Page	1001
Page Count	10
Starting Page	992
File Format	PDF
ISSN	01676997
e-ISSN	15730646
Journal	Investigational New Drugs
Issue Number	4
Volume Number	33
Language	English
Publisher	Springer US
Publisher Date	2015-08-01
Access Restriction	Open
Rights Holder	Springer US
Subject Keyword	Pharmacology (medical) Oncology Pharmacology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy

A novel approach to translymphatic chemotherapy targeting sentinel lymph nodes of patients with oral cancer using intra-arterial chemotherapy - preliminary study

Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin

Immune therapeutic targeting of glioma cancer stem cells

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

Chemotherapy targeting cancer stem cells

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α

Xilonix, a Novel True Human Antibody Targeting the Inflammatory Cytokine Interleukin-1 alpha, in Non-Small Cell Lung Cancer

Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy

Similar Documents

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy

A novel approach to translymphatic chemotherapy targeting sentinel lymph nodes of patients with oral cancer using intra-arterial chemotherapy - preliminary study

Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin

Immune therapeutic targeting of glioma cancer stem cells

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

Chemotherapy targeting cancer stem cells

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α

Xilonix, a Novel True Human Antibody Targeting the Inflammatory Cytokine Interleukin-1 alpha, in Non-Small Cell Lung Cancer

Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy